Selection of Therapeutic Drugs for COVID-19 Infection in Adults with Chronic Kidney Disease Based on Medical Evidence
Chronic kidney disease (CKD) is characterized by abnormal urine test or progressive kidney function decline. Patients with CKD are at a higher risk of COVID-19 infection with higher conversion and mortality rates after infection for their reduced kidney function, long-term use of immunosuppressive agents or combination of underlying diseases. Therefore, rational drug use is particularly important for CKD patients combined with COVID-19 infection. This article summarizes special considerations for the use of relevant medications in patients with CKD by integrating the current evidence of medications for the treatment of COVID-19 infection, including antiviral drugs, anti-inflammatory drugs, antithrombotic drugs, convalescent plasma and neutralizing monoclonal antibodies, as well as commonly used symptomatic drugs of respiratory system (such as antfebrile, antisputum and cough medicine and anti-allergic drugs), high lighting the modified medication regiments according to kidney function levels, in order to provide a reference for clinical professionals, assist in clinical decision-making and rational drug use, and ensure clinical efficacy and safety..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Zhongguo quanke yixue - 26(2023), 26, Seite 3220-3229 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
SU Guobin, LING Xitao, DUAN Ruolan, ZHANG La, XU Yuan, PENG Yu, HOU Haijing, LIU Xusheng, LU Fuhua [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Kidney diseases|chronic kidney disease|corona virus disease 2019|dialysis|therapy|medication|guideline|evidence-based medicine |
|---|
| doi: |
10.12114/j.issn.1007-9572.2023.0156 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ091489245 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ091489245 | ||
| 003 | DE-627 | ||
| 005 | 20240412093850.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240412s2023 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.12114/j.issn.1007-9572.2023.0156 |2 doi | |
| 035 | |a (DE-627)DOAJ091489245 | ||
| 035 | |a (DE-599)DOAJ710d7925938747f4bc6b969de5f9e409 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 0 | |a SU Guobin, LING Xitao, DUAN Ruolan, ZHANG La, XU Yuan, PENG Yu, HOU Haijing, LIU Xusheng, LU Fuhua |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Selection of Therapeutic Drugs for COVID-19 Infection in Adults with Chronic Kidney Disease Based on Medical Evidence |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Chronic kidney disease (CKD) is characterized by abnormal urine test or progressive kidney function decline. Patients with CKD are at a higher risk of COVID-19 infection with higher conversion and mortality rates after infection for their reduced kidney function, long-term use of immunosuppressive agents or combination of underlying diseases. Therefore, rational drug use is particularly important for CKD patients combined with COVID-19 infection. This article summarizes special considerations for the use of relevant medications in patients with CKD by integrating the current evidence of medications for the treatment of COVID-19 infection, including antiviral drugs, anti-inflammatory drugs, antithrombotic drugs, convalescent plasma and neutralizing monoclonal antibodies, as well as commonly used symptomatic drugs of respiratory system (such as antfebrile, antisputum and cough medicine and anti-allergic drugs), high lighting the modified medication regiments according to kidney function levels, in order to provide a reference for clinical professionals, assist in clinical decision-making and rational drug use, and ensure clinical efficacy and safety. | ||
| 650 | 4 | |a kidney diseases|chronic kidney disease|corona virus disease 2019|dialysis|therapy|medication|guideline|evidence-based medicine | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 773 | 0 | 8 | |i In |t Zhongguo quanke yixue |d Chinese General Practice Publishing House Co., Ltd, 2024 |g 26(2023), 26, Seite 3220-3229 |w (DE-627)DOAJ090664779 |x 10079572 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2023 |g number:26 |g pages:3220-3229 |
| 856 | 4 | 0 | |u https://doi.org/10.12114/j.issn.1007-9572.2023.0156 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/710d7925938747f4bc6b969de5f9e409 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.chinagp.net/fileup/1007-9572/PDF/20230156.pdf |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1007-9572 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2023 |e 26 |h 3220-3229 | ||